[Immuno-oncology of head and neck tumors].

Treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) is nowadays multidisciplinary. Therapeutic concepts include modern surgical and radiation techniques as well as systemic therapies. However, the prognosis of these patients is still poor for all stages. In the recurrent or metastatic situation after definitive therapy, there is an indication for palliative systemic treatment, whereby classical platinum-based chemotherapy and the monoclonal epidermal growth factor receptor (EGFR) antibody cetuximab are established, and immunotherapy (IO) has recently been proven a potent treatment option. In this review, the results of trials relevant for approval of checkpoint inhibitors in the palliative setting after platinum failure, as well as ongoing trials evaluating their impact as first-line treatment, in combination with definitive or adjuvant radiation, preoperatively in resectable head and neck cancers, or in combination with other IO therapeutics shall be discussed.